AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) diabetes drug Onglyza doesn't reduce heart...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca's (AZN) and Bristol-Myers Squibb's (BMY) diabetes drug Onglyza doesn't reduce heart risks, a large-scale study shows, with patients who suffer from the Type 2 version of the disease not experiencing fewer strokes, heart attacks and other adverse events than those who took a placebo. Investors had hoped that a demonstrable cardiovascular benefit for Onglyza, which generated sales of $709M in 2012, would give it an edge over rival treatments and revive slowing demand. (PR)